{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-23-002900","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2023-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.492377+00:00","generated_at":"2026-06-10T02:18:31.692149+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Relmada Therapeutics updates corporate presentation on CNS pipeline","bullets":["Filed corporate presentation dated October 10, 2023 as Exhibit 99.1.","No specific financial or clinical data disclosed in the 8-K filing.","Presentation title: 'Targeting Major Advances in the Treatment of CNS Disorders'."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-23-002900","json":"https://secwatch.observer/filing/0001013762-23-002900.json","markdown":"https://secwatch.observer/filing/0001013762-23-002900.md","text":"https://secwatch.observer/filing/0001013762-23-002900.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000101376223002900/0001013762-23-002900-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000101376223002900/ea186591-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T02:18:31.692149+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}